COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.03.24.21254227: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This analysis has several limitations. We assumed that COVID-19 vaccines are equally effective among individuals with cardiovascular risk factors as among those without cardiovascular risk factors. While there was no evidence …
SciScore for 10.1101/2021.03.24.21254227: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This analysis has several limitations. We assumed that COVID-19 vaccines are equally effective among individuals with cardiovascular risk factors as among those without cardiovascular risk factors. While there was no evidence from the randomized, controlled trials of COVID-19 vaccinations to indicate that the efficacy of these vaccines varies according to the recipient’s age, sex or cardiovascular risk factors, data that have yet to be peer-reviewed suggest that among 248 healthcare workers receiving the BNT 162b2 vaccine, the humoral immune response was larger among those with a “normal” body-mass index as compared with a higher body-mass index(12). Also, while we demonstrate a reduction in the number-needed-to-vaccinate to reduce mortality if those with cardiovascular risk factors are vaccinated earlier, we have not estimated the number of quality-adjusted life-years gained by such a strategy. If individuals without cardiovascular risk factors gain more quality-adjusted life-years through COVID-19 vaccination, this may attenuate the apparent advantages of preferentially vaccinating those with cardiovascular risk factors earlier. We have not evaluated the potential impact of preferentially vaccinating adults with chronic diseases other than obesity, diabetes and hypertension because there were limited numbers of these diseases in the PURE data. Public Health England guidance includes diseases such as dementia, kidney disease and recent cancer as conditions warranting earlier...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
